GlassScriptPhysician profile
Michelle A Verduzco
NPI 1477191799
$9,008.62
in general payments reported to CMS, 2019-2025
49 companies · $962 in 2025
The $962 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,509 · 2022: $2,122 · 2023: $1,909 · 2024: $1,506 · 2025: $962.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,377.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $801.30 | 2021-2025 | Calquence, Lynparza, Farxiga |
| Lilly USA, LLC | $754.23 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $730.11 | 2021-2025 | |
| Novo Nordisk INC | $604.25 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Servier Pharmaceuticals LLC | $464.45 | 2022 | |
| Daiichi Sankyo INC. | $373.79 | 2021-2023 | Enhertu |
| Mayne Pharma Commercial LLC | $284.80 | 2021 | |
| Pfizer INC. | $283.52 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $278.04 | 2021-2024 | |
| Exelixis INC. | $243.70 | 2023-2024 | Cabometyx |
| Astellas Pharma US INC | $234.27 | 2021-2024 | Veozah |
| Eisai INC. | $215.48 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $214.56 | 2021-2023 | Vaxneuvance, Pneumovax 23, Gardasil 9 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $212.71 | 2022-2023 | Trulance |
| Glaxosmithkline, LLC. | $206.22 | 2021-2024 | Jemperli, Shingrix, Bexsero |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Verduzco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.